Clinical Trial Update: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL [Phase 1, Phase 2]

View source ↗

Summary

Mustang Bio's MB-106 study in relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia has been terminated, covering Phase 1 and Phase 2 portion…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• MB-106

Snippet

Sponsor: Mustang Bio | Conditions: Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent | Phase 1, Phase 2 | Status: TERMINATED